SynthesisFrontiers in immunology2026
Efficacy and safety of antibody-drug conjugate based therapy in locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis of emerging clinical evidence.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Locally advanced or metastatic urothelial carcinoma (la/mUC) is associated with poor prognosis and limited treatment options. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic approach. While previous meta-analyses have shown the efficacy and safety of ADCs in UC, the rapid development of new ADC agents and combination therapies necessitates an updated and comprehensive evidence synthesis. Materials and methods: A comprehensive search was performed in PubMed, Embase, Cochrane Library, and Web of Science from inception to September 2025. Interested outcomes include overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AES). RoB 2.0, ROBINS-I tools and GRADE framework were used for quality assessment. Results: A total of 30 studies (5 RCTs and 25 single-arm trails), involving 3,631 patients, were included. Network meta-analysis showed that, compared with standard therapy, enfortumab vedotin (EV) in combination with pembrolizumab significantly improved OS (HR = 0.63, 95%CI: 0.43-0.92), ORR (OR = 3.33, 95% CI: 1.65-6.74), and PFS (HR = 0.48, 95% CI: 0.41-0.57). The safety results indicate that the ADC agents have a higher incidence rate of ≥3AES. The analysis of single-arm trails revealed that bulumtatug fuvedotin combined with toripalimab achieved an ORR as high as 88% (95% CI: 73%-96%), while disitamab vedotin-based combination therapy showed the longest median OS. Conclusions: This study provides a comprehensive synthesis of the latest clinical evidence on ADC-based monotherapy and combination regimens for la/mUC. The findings confirm the compelling efficacy and manageable safety profile of ADCs in this setting, while also underscoring the need for further clinical trials to validate and refine personalized treatment strategies. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD 420251114022.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.